Faster‐acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart

AIMS: To evaluate the pharmacokinetics and pharmacodynamics of faster‐acting insulin aspart and insulin aspart in a randomized, single‐centre, double‐blind study. METHODS: Fifty‐two patients with type 1 diabetes (mean age 40.3 years) received faster‐acting insulin aspart, insulin aspart, or another...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Diabetes Obes Metab
Egile Nagusiak: Heise, T., Hövelmann, U., Brøndsted, L., Adrian, C. L., Nosek, L., Haahr, H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Blackwell Publishing Ltd 2015
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5054830/
https://ncbi.nlm.nih.gov/pubmed/25846340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12468
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak